Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

OBJECTIVE: To assess the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in a phase II trial in adult patients with active systemic lupus erythematosus (SLE). METHODS: Adults with active SLE were enrolled from 162 sites in 17 countries. Patients (n = 363) we...

Descripción completa

Detalles Bibliográficos
Autores principales: Morand, Eric, Pike, Marilyn, Merrill, Joan T., van Vollenhoven, Ronald, Werth, Victoria P., Hobar, Coburn, Delev, Nikolay, Shah, Vaishali, Sharkey, Brian, Wegman, Thomas, Catlett, Ian, Banerjee, Subhashis, Singhal, Shalabh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2022
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100399/
https://www.ncbi.nlm.nih.gov/pubmed/36369798
http://dx.doi.org/10.1002/art.42391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100399/
https://www.ncbi.nlm.nih.gov/pubmed/36369798
http://dx.doi.org/10.1002/art.42391

Ejemplares similares